Nature Reviews Cardiology, Published online: 22 October 2025; doi:10.1038/s41569-025-01228-w
New evidence from five randomized trials suggests that withholding β-blockers after myocardial infarction (MI) is safe for carefully selected, low-risk patients. However, even if β-blockers are not required to treat ventricular dysfunction, hypertension or arrhythmias, it might still be wiser to continue treatment during the vulnerable period immediately after MI and withdraw treatment several months later.]]>Nature Reviews Cardiology, Published online: 16 October 2025; doi:10.1038/s41569-025-01222-2
In this Review, Zhao and colleagues summarize the major challenges in the implementation of preventative strategies for cardiovascular disease in China and discuss the potential value of digital health-care and artificial intelligence technologies in overcoming these challenges.]]>Nature Reviews Cardiology, Published online: 14 October 2025; doi:10.1038/s41569-025-01225-z
Women in cardiology have long faced barriers, but their leadership is redefining the field. By turning bias into opportunity and exclusion into inclusion, initiatives such as Women As One are opening doors, advancing equity and shaping a more innovative, representative future for cardiovascular care.]]>Nature Reviews Cardiology, Published online: 13 October 2025; doi:10.1038/s41569-025-01224-0
In patients with chronic coronary syndrome and an indication for oral anticoagulation, whether continuation of antiplatelet therapy in the initial phase after percutaneous coronary intervention is appropriate in Western populations with high atherothrombotic risk was previously unclear. The AQUATIC trial now shows that continuation of antiplatelet therapy increases the risk of both bleeding and ischaemic events in these patients.]]>Nature Reviews Cardiology, Published online: 10 October 2025; doi:10.1038/s41569-025-01226-y
In patients with residual inflammation after acute myocardial infarction, antibody-mediated antagonism of the oxidized LDL receptor LOX1 does not induce significant regression of noncalcified atherosclerotic plaque volume over the course of 9 months compared with placebo, according to the GOLDILOX-TIMI 69 trial.]]>Nature Reviews Cardiology, Published online: 06 October 2025; doi:10.1038/s41569-025-01220-4
In this Review, Nicholas Chew and colleagues use epidemiological data on the cardiovascular–liver–metabolic disease syndemic to illustrate current and future projections on the burden of these diseases and their risk factors, and propose a unified framework for integrating and implementing effective multisystem interventions to tackle key components of this syndemic.]]>Nature Reviews Cardiology, Published online: 02 October 2025; doi:10.1038/s41569-025-01211-5
In this Review, Omerovic and Redfors discuss the historical background, clinical presentation and current best practices for the diagnosis and management of Takotsubo syndrome. They also summarize the current understanding of the complex pathophysiology of Takotsubo syndrome, highlighting ongoing and potential future research directions.]]>Nature Reviews Cardiology, Published online: 01 October 2025; doi:10.1038/s41569-025-01212-4
In this Review, Paterson and colleagues describe how bioelectronic approaches involving site-specific targeting of the autonomic nervous circuit could be used to treat cardiovascular disease, and reflect on current bioelectronic modalities, their limitations and future ways to improve therapeutic efficiency.]]>